Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021

NEXT STORY
Philips delivers Q2 sales of EUR 4.2 billion, with 9% comparable sales growth; net income amounts to EUR 153 million and Adjusted EBITA margin improves 280 basis points to 12.6%; company announces EUR 1.5 billion share buyback program
PREV STORY
New to The Street TV Announces Its #202 show on Bloomberg TV, Tonight, Friday, July 23, 2021 @ 9:30 PM PT
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Diaxonhit: 2015 Consolidated Income: EU29.5 M

PARIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- DIAXONHIT (Alternext : ALEHT, FR0004054427), a French ...

author_avatar
NASDAQ Market News

Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors

CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage ...

author_avatar
NASDAQ Market News

XBiotech Provides Update on Xilonix™ Phase III Programs in US and EU

AUSTIN, Texas, July 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation ...

author_avatar
NASDAQ Market News